Biological E and GVK BIO Announce Strategic R&D Partnership
GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and BE Pharmaceuticals Inc (BE Inc), a rapidly growing pharmaceutical company that develops, manufactures and markets complex and critical injectable products, announced a strategic collaboration in drug product development.
As part of the partnership, GVK BIO will develop certain set of injectable products for BE Inc. Development work will include Pre-Formulation studies, Formulation Development, Analytical Method Development and Technology Transfer to a BE facility. The goal of the collaboration will be the successful regulatory submissions and marketing authorizations for the products in the US, Europe and RoW markets.
“GVK BIO’s Formulations Development team has the technical expertise and track record to deliver on projects, and we look forward to working with the BE team to accelerate product development timelines and reduce cost to market,” said Manni Kantipudi, Director & Chief Executive Officer, GVK BIO.
“We are excited to work with GVK BIO, an established CRDO,” said Narender Mantena, CEO, Speciality Generic Injectable, BE Pharmaceuticals. “This collaboration will support BE in building a robust pipeline, especially for critical injectable products."
About GVK BIO
GVK BIO, a Contract Research & Development Organization that services the global Pharmaceutical industry is headquartered in Hyderabad, India and has five sites across the globe. Established in 2001, GVK BIO serves large and small pharma clients across the R&D value chain with a focus on speed and quality, ensuring safety and compliance. GVK BIO’s team of over 2200 scientists, are supported by a no-conflict business model, modern facilities, strong customer-centric culture, and focus on bringing their customers’ products to market rapidly and cost effectively. www.gvkbio.com
About Biological E. Limited
Biological E. Limited (BE) is a privately held company established in 1953. BE is a globally focused biopharmaceutical company, which develops, manufactures and markets innovative vaccines and biologics that respond to healthcare needs worldwide. The company’s product development efforts are driven by an internationally experienced management team and the company has several strategic partnerships with leading biotechnology and pharmaceutical companies and research institutes around the world.
BE Pharmaceuticals Inc is a subsidiary of Biological E. Limited and focuses on Speciality Generic Injectables. www.biologicale.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Recognized in the 2019 Dow Jones Sustainability World Index19.9.2019 08:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score. In addition, Takeda was named for the 10th consecutive year in the Dow Jones Sustainability Asia Pacific Index. The Dow Jones Sustainability Indices are an independent indication of the Company’s strong corporate environmental, social and governance (ESG) performance. “Takeda’s commitment to creating and preserving value through environmental, social and governance initiatives is an important part of our role as a patient-centric and values-based global biopharmaceutical leader,” said Christophe Weber, President and CEO. “We understand the significance of sustainable business practices, and we are proud to be recognized for Takeda’s global impact and long-term commitment to building a brighter future.” Takeda achieved more than double the average pharmaceutical indus
INSHUR Strengthens Its Senior Team With the Appointment of Simon Logan From Uber18.9.2019 23:36:00 EEST | Press release
INSHUR, the first mobile app to offer Uber drivers insurance in just three minutes, has strengthened its relationship with the ride-sharing app by appointing its former Legal Director of Insurance, EMEA, Simon Logan as VP of Commercial & Legal. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190918005972/en/ Simon Logan - VP Commercial & Legal (Photo: Business Wire) Simon's primary responsibility at Uber was providing legal and commercial counsel throughout the 40 countries Uber is active in the EMEA region. Before this, he was Head of Legal at RSA Insurance Group in London. INSHUR is one of the fastest-growing “insurtechs” and is backed by Munich Re Digital Partners (MRDP). The transatlantic team, based in New York and Brighton, UK, has built a proprietary technology platform to provide insurance to professional drivers globally. INSHUR sold $24M of premium in the first 12 months of operation in 2018 in New York alone and ha
CORRECTING and REPLACING Three Hospital Systems Earn Five-Star Award from Patient Safety Movement Foundation18.9.2019 23:29:00 EEST | Press release
In the release dated Sept. 17, 2019, the word "ranking" has been replaced with "award" throughout the release. The corrected release reads: THREE HOSPITAL SYSTEMS EARN FIVE-STAR AWARD FROM PATIENT SAFETY MOVEMENT FOUNDATION Award demonstrates organizations’ commitment to eliminating preventable patient deaths On the first World Patient Safety Day, the Patient Safety Movement Foundation (PSMF) announces that it has awarded Dignity Health, MedStar Health and the UPMC with its five-star award for making commitments in alignment with PSMF’s 18 evidence-based Actionable Patient Safety Solutions (APSS). APSS include solutions designed to help hospitals eliminate preventable patient deaths. Preventable deaths are the third leading cause of death in the U.S. “More than 200,000 patients die from preventable hospital errors in the U.S., and 4.8 million across the globe. Those numbers are simply not acceptable but also unthinkable,” said Dr. David Mayer, PSMF CEO. “Our 5-Star award acknowledges t
IFF to Present at Bernstein Strategic Decisions Conference September 2518.9.2019 23:15:00 EEST | Press release
Regulatory News: IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition & ingredients today announced that the Company’s management will speak at the Bernstein Strategic Decisions Conference in London on Wednesday, Sept 25, 2019 at 10:30 AM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/2019091800548
Ceravision Ltd: Ground Breaking Results for New Horticulture Light Technology18.9.2019 19:14:00 EEST | Press release
Ceravision Limited, inventor of a new and unique scientific approach to horticulture lighting, today announced the results of trials undertaken over the last six months with a group of leading horticulture businesses. Results from independently conducted trials with Bridge Farm Group on licenced industrial hemp have demonstrated an increase in yield and potency of 40% compared to other lighting solutions. Trials elsewhere on salad crops have also revealed benefits - faster growth, fewer pesticides and less waste. Exploiting its innovative plasma light technology, Ceravision’s new and patented approach to horticultural lighting is based on the ability to produce unique light spectra with unparalleled levels of UV-A and UV-B. This UV spectral range is crucial for indoor cultivation. UV can benefit plants as it enhances the production of the secondary metabolites that act as ‘sunscreens’ and boost aroma, flavonoids, terpenes, colour, nutritional and medicinal values. UV can also improve d
Larger, healthier, more plentiful — Study proves House Wellness Foods’ Feed LP20® improves stock at the cellular level.18.9.2019 18:28:00 EEST | Press release
Eons ago, the progress of humankind was thrust forward with the development of farming. Today that progress is challenged simultaneously by climatic and socioeconomic forces, and the future hangs in the balance. Our fundamental need is to nourish the world, and the means to achieve that is increased efficiency in agriculture and aquaculture. To this end, House Wellness Foods has released yet another groundbreaking clinical study showing that its pioneering, immunobiotic-based Feed LP20®, with the primary ingredient, heat-killed Lactobacillus plantarum L-137 (HK L-137), demonstrably increases the farming output, size, and health of genetically-improved farmed tilapia (GIFT), a food with endless potential for feeding diverse populations across the globe. The conclusions of this study could have world-altering impact on the field of aquaculture, and the company will be sharing these at Aquaculture Europe, taking place in Berlin, October 7-10, where one of the study’s directors, Mahmoud A.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom